Biogen quarter-one results disappoint Wall Street as Tecfidera sales slow
Sales of Tecfidera beat the average analyst estimate by about $36 million last quarter. Tecfidera raked in sales of $824.9 million in the first quarter ended March 31, compared with $506 million a year earlier, but missed consensus projections of about $931 million, according to Deutsche Bank.
